Lotte Biologics completes construction of a biomanufacturing production plant at its Songdo Bio Campus in Incheon, just west of Seoul. The company says the facility marks a major step toward becoming a global biopharmaceutical player, with Plant 1 set to begin commercial operations in 2028.

The plant covers nearly 100,000 square meters and includes a production building and a wastewater treatment facility. Lotte Biologics describes an annual production capacity of 120,000 liters and says the new site will strengthen its manufacturing base in Korea alongside its existing facility in Syracuse, New York, which it acquired in 2023.

Korea Times foregrounds the investment as part of Lotte Group’s future growth, highlighting remarks by Lotte Group Chairman Shin Dong-bin. Yonhap provides essentially the same announcement in two separate datelined versions, emphasizing the completion and the company’s stated global expansion aim while adding location framing around Incheon and Seoul.